CEO of CytoDyn, Dr. Nader Pourhassan, Shares The Progress of The Company’s Leronlimab Trials with The Stock Day Podcast

Oct 10, 2019, 11:30 AM
The Stock Day Podcast welcomed CytoDyn Inc. (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.